10031417Non-invasive quantum sensing for continuous glucose monitoringClosedCollaborative R&DISCFThe objective of the project is to conduct in-vitro feasibility studies for a second- generation quantum sensor, codenamed LUX1, that optically monitors glucose in a revolutionary new way. Unlike currently available sensors, LUX1 will allow people living with diabetes (PLWD) to conveniently measure real-time glucose levels without drawing blood or breaking the skin surface, simply by bringing their finger or wrist into contact with the device. The vision for LUX1 is initially a point- of-care device and we aim to miniaturise it into a smartwatch-like wearable, e.g., Apple watch, aligning with current trends of measuring multiple vitals all in one device. Our innovative approach will be instrumental in tackling a significant worldwide problem. Currently, there are around 463M diabetes sufferers worldwide and this is predicted to rise to 700M over the next 25 years, with millions of additional undiagnosed cases. Diabetes significantly reduces life expectancy -- Type I on average by more than 20 years, and up to 10 years for Type II. In the UK, there are around 500 premature deaths every week and the NHS spend 10% of the annual budget contributing to the treatment of diabetes and the complications, equating to an expenditure of £10B per year (or £192M per week). Despite the growing severity of the situation, many people are still using invasive, non- reusable and non-cost-effective methods to monitor glucose. This demonstrates a compelling need for next-generation glucose monitors, like LUX1, to help PLWD/healthcare professionals to be more proactive in diabetes management to reduce the number of amputations/premature deaths, and associated costs. To develop our LUX1 prototype, we have split the project into four work packages: * Business development * Sensor design/manufacture * Sensor packaging/testing * In-vitro feasibility studies